05/22/06

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1632

AMLOT ET AL.

Examiner: R. Harrison

APPLICATION NO: 09/770,002 FILED: JANUARY 25, 2001

FOR: USE OF CD25 BINDING MOLECULES IN THE TREATMENT OF

RHEUMATOID ARTHRITIS OR SKIN DISEASES

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

PETITION TO REVIVE UNDER 37 CFR 1.137(b).

Sir:

Applicants respectfully request that the above-identified application be revived under the provisions of 37 CFR 1.137(b).

This application became abandoned by failure to file an Appeal Brief or other subsequent paper to the Granted Petition dated June 2, 2004, within the six month statutory period which expired on December 2, 2004.

Enclosed with this Petition is a Request for Continued Examination (RCE) Transmittal in response to the Granted Petition as required by 37 CFR 1.17(c).

In accordance with 37 CFR 1.137(b)(2), the Commissioner is hereby authorized to charge the fee of \$1,500 required by 37 CFR 1.17(m) to Deposit Account No. 19-0134 in the name of Novartis Corporation. A duplicate copy of this Petition is also enclosed.

In accordance with 37 CFR 1.137(b)(3), it is respectfully submitted that the entire delay in filing the required Appeal Brief or other subsequent paper from the due date of December 2, 2004 until the filing of the instant, grantable petition was unintentional.

Respectfully submitted,

Thomas R. Savitsky Attorney for Applicants

Reg. No. 31,661

Phone No. (862) 778-7909

Novartis

Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080

Date: May 16, 2006

Encls.: extra copy of Petition

RCE Transmittal

05/23/2006 MAHMED1 00000066 190134 09770002

01 FC:1453

1500.00 DA